Research programme: type II DNA topoisomerase inhibitors - Sunshine Biopharma

Drug Profile

Research programme: type II DNA topoisomerase inhibitors - Sunshine Biopharma

Alternative Names: Adva-27a; Adva-32a; Carbon-difluoro etoposide derivatives - Advanomics/Sunshine Biopharma; Difluoro-Etoposide; Topo2 inhibitors - Advanomics/Sunshine Biopharma; Topoisomerase II inhibitors - Advanomics/Sunshine Biopharma

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Advanomics
  • Developer Advanomics; Sunshine Biopharma
  • Class Antineoplastics; Dioxanes; Dioxolanes; Lactones; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Pancreatic cancer; Small cell lung cancer; Uterine cancer

Most Recent Events

  • 26 Apr 2017 Sunshine Biopharma plans a phase I trial for Pancreatic and Breast cancer (Second-line treatment or greater; Treatment-experienced in USA and Canada in mid 2018 (3239670)
  • 15 Mar 2016 Sunshine Biopharma amends its patent purchase agreements for the worldwide patents and rights related to Adva 27a
  • 28 Dec 2015 Sunshine Biopharma acquires all rights to intellectual properties for Adva 27a from Advanomics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top